# The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

> **NCT06217185** · PHASE4 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 100 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Advanced Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Trastuzumab
- **DRUG:** Taxanes
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06217185
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-02
- **Primary completion:** 2025-12-11
- **Final completion:** 2027-06-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06217185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06217185, "The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06217185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*